Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug 30;61(9):3534-3546.
doi: 10.1093/rheumatology/keac060.

Pharmacological treatment in adult patients with CRPS-I: a systematic review and meta-analysis of randomized controlled trials

Angelo Fassio  1 , Alessandro Mantovani  2 , Davide Gatti  1 , Maurizio Rossini  1 , Ombretta Viapiana  1 , Irene Gavioli  1 , Camilla Benini  1 , Giovanni Adami  1
Affiliations
Meta-Analysis

Pharmacological treatment in adult patients with CRPS-I: a systematic review and meta-analysis of randomized controlled trials

Angelo Fassio et al. Rheumatology (Oxford). .

Abstract

Objective: Several pharmacological treatments have been proposed for the treatment of complex regional pain syndrome type-I (CRPS-I) in adults, but data regarding the efficacy of various agents for this disease is scarce. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) to analyse the efficacy of the various pharmacological approaches in adults with CRPS-I.

Methods: We systematically searched PubMed, Scopus, and Web of Science databases from the inception date to 30 June 2021 to identify placebo-controlled or active-controlled RCTs using bisphosphonates, ketamine, CSs, anti-epileptics, NSAIDs/COXIBs, opiates, antidepressants, scavengers/magnesium sulphate or IVIGs for the treatment of CRPS-I. The primary outcomes included changes in the visual analogue scale (VAS) or numeric rating scale (NRS) for pain before and after treatment.

Results: We included 20 placebo-controlled or active-controlled RCTs (including a total of 818 adults with CRPS-I) that used bisphosphonates (n = 7), ketamine (n = 2), CSs (n = 2), anti-epileptics (n = 1), NSAIDs/selective inhibitors of cyclooxygenase-2 (COXIBs) (n = 2), scavengers/magnesium sulphate (n = 5), or IVIGs (n = 1) to treat CRPS-I during a median follow-up of 26 weeks. Treatment with bisphosphonates showed a significant reduction in the values of the VAS/NRS pain scale compared with placebo or reference therapy (random effects weighted mean difference [WMD]: -23.8, 95% CI: -28.0 to -19.6; I2 = 36.4%). Treatment with ketamine also documented a reduction in the values of the VAS/NRS for pain (random effects WMD: -8.27, 95% CI: -12.9 to -3.70; I2 = 0%). Treatment with other agents did not reduce the values of the VAS/NRS assessments of pain.

Conclusion: This systematic review and meta-analysis supports the recommendation of parenteral bisphosphonates as the first-line agent in the treatment of CRPS-I.

Trial registration: Open Science Framework registries, https://osf.io/et9gu/, osf.io/et9gu.

Keywords: algodystrophy; antidepressants; bisphosphonates; bone marrow oedema; complex regional pain syndrome; corticosteroids.

PubMed Disclaimer

MeSH terms